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Tel: (847) 303-5003 Fax: (847) 303-5601 www.ihmainc.com Table 1 . In vitro activity of tigecycline and comparative agents against m i n o c y c l i n e -r e s i s t a n t Enterobacteriaceae. Table 3 . In vitro activity of tigecycline and comparative agents against minocycline-resistant gram-positive pathogens.
 All isolates were derived from blood, respiratory tract, urine (no more than 25% of all isolates), skin, wound, body fluids, and other defined sources. Only one isolate per patient was accepted into the study. More than 102,519 clinical isolates were collected and tested between 2004 to 2007 from 484 investigative sites from 53 countries globally. Isolates were identified to the species level and tested at each site by the participating laboratory.  Organism collection, transport, confirmation of organism identification, as well as, development and management of a centralized database was coordinated by Laboratories International for Microbiology Studies (LIMS), a division of International Health Management Associates, Inc. located in Schaumburg, IL, USA.  All organisms were deemed clinically significant by local participant criteria. Isolate inclusion was independent of medical history, antimicrobial use, age or gender. All sites identified each study isolate utilizing local laboratory site criteria.  Minimum inhibitory concentrations (MICs) were determined by the CLSI recommended broth microdilution testing method [12] . Antimicrobial agents and concentrations tested (expressed in mcg/mL) were as follows: gram positive panel: amoxicillin/clavulanic acid (0.03/0.015-8/4, tested using a 2:1 ratio of amoxicillin:clavulanic acid; reported concentrations refer to amoxicillin); ampicillin (0.06-16); ceftriaxone (0.03-64); meropenem (0.12-16, MicroScan and TREK panels); linezolid (0. Table 2 . In vitro activity of tigecycline and comparative agents against minocycline-resistant nonfermenting gram-negative pathogens. † Resistance phenotypes and drug susceptibilities as defined in CLSI document M100-S17, 2007; na=Tigecycline breakpoints not determined for this species. Table 4 . In vitro activity of tigecycline and comparative agents against minocycline-resistant fastidious respiratory pathogens. † Resistance phenotypes and drug susceptibilities as defined in CLSI document M100-S17, 2007; na=Tigecycline breakpoints not determined for this species
CONCLUSIONS


Tigecycline demonstrated minimal cross-resistant with minocycline and a variability that was species dependent. There was no cross-resistance of tigecycline with minocycline against E. coli and Acinetobacter species. Tigecycline MICs against minocycline-resistant Klebsiella and Serratia ranged from 4-to 16-fold lower than minocycline. Neither tigecycline or minocycline demonstrated significant activity against P. aeruginosa.
Tigecycline demonstrated potent in vitro activity against gram-positive strains that were resistant to minocycline. More than 97% of all minocycline-resistant staphylococci and enterococci were inhibited by tigecycline at the defined susceptibility breakpoints of 0.5 and 0.25 mcg/mL, for staphylococci and enterococci (vancomycin-susceptible), respectively.
The MIC 90 values of tigecycline were 0.5 and <0.12 mcg/ mL against the minocycline-resistant fastidious respiratory pathogens, H. influenzae and S. pneumoniae, respectively, including penicillin-resistant S. pneumoniae.  Tigecycline exhibited potent in vitro activity against minocycline-resistant strains and may be considered in such cases where the tetracyclines and their analogs have been previously excluded. 
